Trusted by Leading Research & Pharma Institutions

Custom CpG ODNs Synthesis Services

Q: What are the different classes of CpG ODNs?

CpG ODNs are classified into three main types: Class A (Type D) features a phosphodiester central CpG palindrome with a phosphorothioate poly-G tail, inducing high IFN-α from pDCs; Class B (Type K) has a full phosphorothioate backbone and strongly activates B cells; Class C combines features of both A and B, making it versatile for multiple immune activation pathways.

Q: What is phosphorothioate modification and why is it important?

Phosphorothioate (PS) modification replaces a non-bridging oxygen atom in the phosphate backbone with sulfur. This modification significantly increases nuclease resistance, extending the half-life of CpG ODNs in serum from minutes to hours. PS-modified CpG ODNs are essential for in vivo applications where enzymatic degradation would otherwise limit effectiveness.

Q: How do I choose the right CpG ODN for my application?

The choice depends on your desired immune response: For high IFN-α production and pDC activation, choose Class A; For strong B-cell activation and NF-κB signaling, choose Class B; For combined effects on both pDCs and B cells, choose Class C. Our scientific team can help optimize your selection based on your specific research goals.

Q: What quality control is performed on each synthesis?

Every CpG ODN undergoes comprehensive quality control including LC-MS or MALDI-TOF mass spectrometry for sequence verification, HPLC or capillary electrophoresis for purity analysis, and endotoxin testing for preclinical and cGMP grades. A detailed Certificate of Analysis (COA) is included with each delivery.

Q: What modifications are available for custom CpG ODNs?

We offer over 200 chemical modifications including: fluorescent labels (FAM, Cy3, Cy5), biotin for affinity applications, various spacer groups (C3, C6, C12), locked nucleic acids (LNA), 2'-O-methyl RNA, and peptide conjugations. Our team can advise on the best modifications for your specific experimental needs.

Q: Can you produce CpG ODNs at cGMP grade for clinical use?

Yes, we offer cGMP-grade CpG ODN synthesis with purity ≥98%, endotoxin levels <0.1 EU/mg, and comprehensive documentation for regulatory submissions. Our scalable production ranges from research scale (mg) to commercial scale (multi-kg), supporting all phases of drug development from preclinical to commercial manufacturing.

Accelerate your TLR9 immunotherapy research with custom CpG oligodeoxynucleotides consistently manufactured to your exact specifications. From standard Class A/B/C sequences to complex modified constructs, we deliver high-purity immunostimulatory oligonucleotides with comprehensive quality verification.

LC-MS Verified

>99% Purity

All Classes

Learn More

Trusted by leading research and pharmaceutical institutions

NIH

Novartis

Johns Hopkins

Bristol Myers

Stanford

Merck

Why Choose Us

All CpG ODN classes (A, B, C, P)

200+ chemical modifications

cGMP-grade production available

Functional verification included

TLR9 Activation

Optimized CpG motifs for immune stimulation

Phosphorothioate PS

Enhanced nuclease resistance

Flexible Scale

mg to multi-kg production

Market CAGR

18.5%

Service Overview

Comprehensive Custom CpG ODN Synthesis Solutions

Our platform delivers high-purity immunostimulatory CpG oligodeoxynucleotides for TLR9 research and immunotherapy development.

All CpG ODN Classes

We provide synthesis of all major immunostimulatory CpG ODN classes including Class A (IFN-α induction, pDC activation), Class B (B-cell activation), Class C (combined effects), and P-class (dimeric structures).

Class A: High IFN-α, strong pDC activation
Class B: Strong B-cell and NF-κB activation
Class C: Combined A + B properties

Quality Verification

Every CpG ODN undergoes rigorous quality control including LC-MS verification, HPLC purity analysis, and optional endotoxin testing to ensure your sequences perform reliably.

LC-MS and MALDI-TOF verification
HPLC purity ≥95% standard
Endotoxin testing available

TLR9 Specificity

Optimized CpG motifs for human and mouse TLR9 receptors.

200+ Modifications

Phosphorothioate, fluorescent labels, biotin, and more.

Scalable Production

From mg research scale to multi-kg cGMP production.

Technology Platform

Advanced Synthesis Technologies

Industry-leading synthesis platforms ensuring high-quality output for every CpG ODN project.

Solid-Phase Synthesis

Automated phosphoramidite chemistry on controlled pore glass (CPG) supports with exceptional coupling efficiency up to 99.5%.

99.5% Efficiency Automated

Phosphorothioate Mod

Phosphorothioate (PS) backbone modifications for enhanced nuclease resistance and serum stability in vivo.

PS Backbone Nuclease Resistant

Quality Verification

Comprehensive analytical characterization using LC-MS, MALDI-TOF, and HPLC for every synthesis batch.

LC-MS HPLC

CpG ODN Classes

Class A (Type D)

PO central CpG palindrome + PS 3' poly-G tail

High IFN-α production
pDC activation
NK cell stimulation

Class B (Type K)

Full phosphorothioate backbone linear structure

Strong B-cell activation
NF-κB signaling
Vaccine adjuvant

Class C (Combined)

Full PS backbone + CpG palindrome

Both pDC & B-cell
IFN-α induction
Most versatile

Specifications

Flexible Options for Diverse Needs

Comprehensive specifications to meet your TLR9 research requirements.

Parameter	Research Grade	Preclinical Grade	cGMP Grade
Purity	≥85% (HPLC)	≥95% (HPLC)	≥98% (HPLC)
Endotoxin	<5 EU/mg	<1 EU/mg	<0.1 EU/mg
Scale Range	50 nmol - 1 μmol	1 - 10 μmol	10 μmol - multi g
Length Range	12 - 50 nt	12 - 100 nt	12 - 200 nt
Modifications	50+ options	100+ options	200+ options
Analysis	LC-MS, CE	LC-MS, HPLC, Endotoxin	Full COA, Stability

Workflow

Streamlined Process from Design to Delivery

Our proven 5-step workflow ensures quality and efficiency at every stage.

Consultation

Sequence design & class selection guidance

Feasibility

Sequence optimization & quote

Synthesis

Automated phosphoramidite synthesis

QC

LC-MS, HPLC verification

Delivery

Lyophilized with COA

Applications

Diverse Applications in Immunotherapy

Our CpG ODN synthesis services support research across multiple fields.

Cancer Immunotherapy

CpG ODNs are potent TLR9 agonists that can reverse tumor immunosuppression and enhance the efficacy of checkpoint inhibitors. They stimulate both innate and adaptive immune responses in the tumor microenvironment.

Intratumoral injection for local immune activation
Combination with anti-PD-1/PD-L1 therapy
NK cell and CTL activation
Pro-inflammatory cytokine induction

Multiple

Clinical trials ongoing

Vaccine Adjuvants

CpG ODNs are FDA-approved vaccine adjuvants that shift immune responses toward Th1-dominant immunity. Heplisav-B, a hepatitis B vaccine with CpG adjuvant, demonstrated superior efficacy in clinical trials.

Enhanced antibody production
Th1-polarized cellular immunity
CD8+ T cell activation
Works with protein and peptide antigens

FDA

Approved adjuvant

TLR9 Research

CpG ODNs are essential tools for studying TLR9 signaling pathways and immune cell activation mechanisms. Our verified sequences ensure reproducible research results.

TLR9 pathway activation studies
B cell and pDC activation assays
Cytokine profiling experiments
Control ODNs included

Validated

Functional verification

Testimonials

What Our Clients Say

Trusted by researchers worldwide for quality and reliability.

"The purity and reproducibility of these CpG ODNs have significantly improved our TLR9 activation studies. LC-MS verification gives us confidence in every batch."

Senior Scientist

Biotechnology Company

"We needed custom modified CpG ODNs with fluorescent labels for our imaging studies. The technical team provided excellent support throughout."

Research Director

Academic Research Institution

"The scalable production capability allowed us to seamlessly transition from research to preclinical studies. Consistent quality every time."

Lead Researcher

Pharmaceutical Company

Scientific Literature

Scientific Foundation

Our platform is backed by peer-reviewed research.

85 Citations

Development of CpG oligodeoxynucleotide TLR9 agonists in anti-cancer therapy

Jin Y, Zhuang Y, Dong X, Liu M. Expert Review of Anticancer Therapy. 2021.

Comprehensive review of TLR9 agonist development and clinical trials in cancer immunotherapy.

View DOI

92 Citations

The Antitumor Efficacy of CpG Oligonucleotides is Improved by Encapsulation in Plant Virus-Like Particles

Various authors. Advanced Science (Wiley). 2021.

Demonstrates enhanced CpG ODN antitumor efficacy through plant VLP encapsulation.

View DOI

78 Citations

A Novel C Type CpG Oligodeoxynucleotide Exhibits Immunostimulatory Activity In Vitro and Enhances Antitumor Effect In Vivo

Various authors. Frontiers in Immunology. 2020.

Novel CpG-C ODN (HP06T07) shows potent immunostimulatory and antitumor activity.

View DOI

45 Citations

Class A CpG oligodeoxynucleotide inhibits IFN-γ-induced signaling and apoptosis in lung cancer

Various authors. Thoracic Cancer. 2020.

A-CpG ODN effects on IFN-γ signaling and PD-L1 expression in lung cancer cells.

View DOI

156 Citations

Class-B CpG-ODN Formulated With a Nanostructure Induces Type I Interferons-Dependent CD8+ T-Cell Response

Various authors. Frontiers in Immunology. 2018.

Nanostructured B-class CpG ODN formulation for enhanced vaccine adjuvant effects.

View DOI

FAQ

Frequently Asked Questions

Find answers to common questions about our CpG ODN synthesis service.

CpG ODNs are classified into three main types: Class A (Type D) features a phosphodiester central CpG palindrome with a phosphorothioate poly-G tail, inducing high IFN-α from pDCs; Class B (Type K) has a full phosphorothioate backbone and strongly activates B cells; Class C combines features of both A and B, making it versatile for multiple immune activation pathways.

Phosphorothioate (PS) modification replaces a non-bridging oxygen atom in the phosphate backbone with sulfur. This modification significantly increases nuclease resistance, extending the half-life of CpG ODNs in serum from minutes to hours. PS-modified CpG ODNs are essential for in vivo applications where enzymatic degradation would otherwise limit effectiveness.

The choice depends on your desired immune response: For high IFN-α production and pDC activation, choose Class A; For strong B-cell activation and NF-κB signaling, choose Class B; For combined effects on both pDCs and B cells, choose Class C. Our scientific team can help optimize your selection based on your specific research goals.

Every CpG ODN undergoes comprehensive quality control including LC-MS or MALDI-TOF mass spectrometry for sequence verification, HPLC or capillary electrophoresis for purity analysis, and endotoxin testing for preclinical and cGMP grades. A detailed Certificate of Analysis (COA) is included with each delivery.

We offer over 200 chemical modifications including: fluorescent labels (FAM, Cy3, Cy5), biotin for affinity applications, various spacer groups (C3, C6, C12), locked nucleic acids (LNA), 2'-O-methyl RNA, and peptide conjugations. Our team can advise on the best modifications for your specific experimental needs.

Yes, we offer cGMP-grade CpG ODN synthesis with purity ≥98%, endotoxin levels <0.1 EU/mg, and comprehensive documentation for regulatory submissions. Our scalable production ranges from research scale (mg) to commercial scale (multi-kg), supporting all phases of drug development from preclinical to commercial manufacturing.

Ready to Start Your Project?

Get a customized quote for your Custom CpG ODNs Synthesis project. Our experts will respond within 24 hours.

No obligation

24h response

Expert consultation

Custom CpG ODNs Synthesis Services

Why Choose Us

TLR9 Activation

Phosphorothioate PS

Flexible Scale

Comprehensive Custom CpG ODN Synthesis Solutions

All CpG ODN Classes

Quality Verification

TLR9 Specificity

200+ Modifications

Scalable Production

Ready to Start Your CpG ODN Project?

Advanced Synthesis Technologies

Solid-Phase Synthesis

Phosphorothioate Mod

Quality Verification

CpG ODN Classes

Flexible Options for Diverse Needs

Streamlined Process from Design to Delivery

Consultation

Feasibility

Synthesis

QC

Delivery

Diverse Applications in Immunotherapy

Cancer Immunotherapy

Vaccine Adjuvants

TLR9 Research

What Our Clients Say

Scientific Foundation

Development of CpG oligodeoxynucleotide TLR9 agonists in anti-cancer therapy

The Antitumor Efficacy of CpG Oligonucleotides is Improved by Encapsulation in Plant Virus-Like Particles

A Novel C Type CpG Oligodeoxynucleotide Exhibits Immunostimulatory Activity In Vitro and Enhances Antitumor Effect In Vivo

Class A CpG oligodeoxynucleotide inhibits IFN-γ-induced signaling and apoptosis in lung cancer

Class-B CpG-ODN Formulated With a Nanostructure Induces Type I Interferons-Dependent CD8+ T-Cell Response

Frequently Asked Questions

Ready to Start Your Project?

Recommended Services

Related Resources

Request a Quote

Custom CpG ODNs Synthesis Services

Why Choose Us

TLR9 Activation

Phosphorothioate PS

Flexible Scale

Comprehensive Custom CpG ODN Synthesis Solutions

All CpG ODN Classes

Quality Verification

TLR9 Specificity

200+ Modifications

Scalable Production

Ready to Start Your CpG ODN Project?

Advanced Synthesis Technologies

Solid-Phase Synthesis

Phosphorothioate Mod

Quality Verification

CpG ODN Classes

Flexible Options for Diverse Needs

Streamlined Process from Design to Delivery

Consultation

Feasibility

Synthesis

QC

Delivery

Diverse Applications in Immunotherapy

Cancer Immunotherapy

Vaccine Adjuvants

TLR9 Research

What Our Clients Say

Scientific Foundation

Development of CpG oligodeoxynucleotide TLR9 agonists in anti-cancer therapy

The Antitumor Efficacy of CpG Oligonucleotides is Improved by Encapsulation in Plant Virus-Like Particles

A Novel C Type CpG Oligodeoxynucleotide Exhibits Immunostimulatory Activity In Vitro and Enhances Antitumor Effect In Vivo

Class A CpG oligodeoxynucleotide inhibits IFN-γ-induced signaling and apoptosis in lung cancer

Class-B CpG-ODN Formulated With a Nanostructure Induces Type I Interferons-Dependent CD8+ T-Cell Response

Frequently Asked Questions

Ready to Start Your Project?

Recommended Services

Related Resources